Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.

Garcia AG, Nedev H, Bijian K, Su J, Alaoui-Jamali MA, Saragovi HU.

Oncogene. 2013 May 16;32(20):2527-33. doi: 10.1038/onc.2012.283. Epub 2012 Jul 16.

PMID:
22797066
2.

Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.

Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD.

Pharm Res. 2007 Dec;24(12):2402-11. Epub 2007 Sep 9.

PMID:
17828616
3.

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

Gianolio DA, Rouleau C, Bauta WE, Lovett D, Cantrell WR Jr, Recio A 3rd, Wolstenholme-Hogg P, Busch M, Pan P, Stefano JE, Kramer HM, Goebel J, Krumbholz RD, Roth S, Schmid SM, Teicher BA.

Cancer Chemother Pharmacol. 2012 Sep;70(3):439-49. doi: 10.1007/s00280-012-1925-8. Epub 2012 Jul 22.

PMID:
22821053
4.

Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.

Cancer Res. 2002 Oct 15;62(20):5703-10.

5.

Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.

Gilbert CW, McGowan EB, Seery GB, Black KS, Pegram MD.

J Exp Ther Oncol. 2003 Jan-Feb;3(1):27-35.

PMID:
12724856
6.

Interaction between Herceptin and taxanes.

Diéras V, Beuzeboc P, Laurence V, Pierga JY, Pouillart P.

Oncology. 2001;61 Suppl 2:43-9. Review.

PMID:
11694787
7.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.

Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.

8.

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.

Yao X, Jiang J, Wang X, Huang C, Li D, Xie K, Xu Q, Li H, Li Z, Lou L, Fang J.

Breast Cancer Res Treat. 2015 Aug;153(1):123-33. doi: 10.1007/s10549-015-3503-3. Epub 2015 Aug 8.

PMID:
26253944
9.
10.

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D.

Oncogene. 1999 Apr 1;18(13):2241-51.

11.

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.

Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C.

Breast Cancer Res Treat. 2009 Nov;118(1):113-24. doi: 10.1007/s10549-009-0412-3. Epub 2009 May 5.

PMID:
19415485
12.

In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.

Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, Liu J, Xiao W, Ling B, Wu Q, Song L, Wei W.

Cancer Immunol Immunother. 2011 Mar;60(3):339-48. doi: 10.1007/s00262-010-0937-7. Epub 2010 Nov 18.

PMID:
21086124
13.

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.

Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2005 Sep-Oct;16(5):1117-25.

PMID:
16173788
14.

Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.

Chen H, Gao J, Lu Y, Kou G, Zhang H, Fan L, Sun Z, Guo Y, Zhong Y.

J Control Release. 2008 Jun 24;128(3):209-16. doi: 10.1016/j.jconrel.2008.03.010. Epub 2008 Mar 19.

PMID:
18450313
15.

Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.

Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS.

PLoS One. 2009 Dec 15;4(12):e8314. doi: 10.1371/journal.pone.0008314.

16.

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab.

Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R.

Int J Nanomedicine. 2011;6:1977-90. doi: 10.2147/IJN.S21523. Epub 2011 Sep 14.

17.

Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.

Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F.

J Control Release. 2010 Jun 15;144(3):324-31. doi: 10.1016/j.jconrel.2010.02.026. Epub 2010 Feb 25.

PMID:
20219607
18.

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.

Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E.

Breast Cancer Res. 2011;13(6):R123. doi: 10.1186/bcr3069. Epub 2011 Nov 30.

19.

Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.

Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M.

Anticancer Res. 2003 Nov-Dec;23(6a):4443-9.

PMID:
14666732
20.

Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.

Hu J, Ljubimova JY, Inoue S, Konda B, Patil R, Ding H, Espinoza A, Wawrowsky KA, Patil C, Ljubimov AV, Black KL.

PLoS One. 2010 Apr 19;5(4):e10108. doi: 10.1371/journal.pone.0010108.

Supplemental Content

Support Center